Literature DB >> 17330070

How can drug discovery for psychiatric disorders be improved?

Yves Agid1, György Buzsáki, David M Diamond, Richard Frackowiak, Jay Giedd, Jean-Antoine Girault, Anthony Grace, Jeremy J Lambert, Husseini Manji, Helen Mayberg, Maurizio Popoli, Alain Prochiantz, Gal Richter-Levin, Peter Somogyi, Michael Spedding, Per Svenningsson, Daniel Weinberger.   

Abstract

Psychiatric disorders such as depression, anxiety and schizophrenia are leading causes of disability worldwide, and have a huge societal impact. However, despite the clear need for better therapies, and major advances in the understanding of the molecular basis of these disorders in recent years, efforts to discover and develop new drugs for neuropsychiatric disorders, particularly those that might revolutionize disease treatment, have been relatively unsuccessful. A multidisciplinary approach will be crucial in addressing this problem, and in the first Advances in Neuroscience for Medical Innovation symposium, experts in multiple areas of neuroscience considered key questions in the field, in particular those related to the importance of neuronal plasticity. The discussions were used as a basis to propose steps that can be taken to improve the effectiveness of drug discovery for psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17330070     DOI: 10.1038/nrd2217

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  63 in total

1.  Dihydropyrimidinone positive modulation of delta-subunit-containing gamma-aminobutyric acid type A receptors, including an epilepsy-linked mutant variant.

Authors:  Ryan W Lewis; John Mabry; Jason G Polisar; Kyle P Eagen; Bruce Ganem; George P Hess
Journal:  Biochemistry       Date:  2010-06-15       Impact factor: 3.162

Review 2.  Comparability of behavioural assays using zebrafish larvae to assess neurotoxicity.

Authors:  J Legradi; N el Abdellaoui; M van Pomeren; J Legler
Journal:  Environ Sci Pollut Res Int       Date:  2014-11-18       Impact factor: 4.223

3.  Thalamic post-inhibitory bursting occurs in patients with organic dystonia more often than controls.

Authors:  K Kobayashi; C C Liu; A L Jensen; J L Vitek; Z Mari; F A Lenz
Journal:  Brain Res       Date:  2013-10-11       Impact factor: 3.252

Review 4.  Scaling brain size, keeping timing: evolutionary preservation of brain rhythms.

Authors:  György Buzsáki; Nikos Logothetis; Wolf Singer
Journal:  Neuron       Date:  2013-10-30       Impact factor: 17.173

5.  Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder.

Authors:  Noa Lipstein; Nanda M Verhoeven-Duif; Francesco E Michelassi; Nathaniel Calloway; Peter M van Hasselt; Katarzyna Pienkowska; Gijs van Haaften; Mieke M van Haelst; Ron van Empelen; Inge Cuppen; Heleen C van Teeseling; Annemieke M V Evelein; Jacob A Vorstman; Sven Thoms; Olaf Jahn; Karen J Duran; Glen R Monroe; Timothy A Ryan; Holger Taschenberger; Jeremy S Dittman; Jeong-Seop Rhee; Gepke Visser; Judith J Jans; Nils Brose
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

Review 6.  NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders.

Authors:  Linda S Brady; Lois Winsky; Wayne Goodman; Mary Ellen Oliveri; Ellen Stover
Journal:  Neuropsychopharmacology       Date:  2008-09-17       Impact factor: 7.853

Review 7.  Drugs in sport: a scientist-athlete's perspective: from ambition to neurochemistry.

Authors:  M Spedding; C Spedding
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

Review 8.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

9.  Drug discovery in psychiatric illness: mining for gold.

Authors:  Greg I Elmer; Neri Kafkafi
Journal:  Schizophr Bull       Date:  2009-03-18       Impact factor: 9.306

Review 10.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.